Medicare Outpatient Physical Therapy Expenditures
Medicare Part B pays for rehabilitation therapy in multiple settings typically used by outpatients, but also by inpatients who have exhausted or do not qualify for Part A benefits. Part B rehabilitation therapy includes physical therapy, occupational therapy, and speech-language pathology (SLP), with physical therapy accounting for 71% of $6.7 billion in Part B therapy spending in 2014. 1 Considerable variation in Part B physical therapy expenditures exists across Medicare beneficiaries [2] [3] ; total expenditures per user in 2011 ranged from a first percentile of $35 to a 99th percentile of $7414, with a mean of $1258. 2 Under a cap-exceptions policy beginning in 2006, 20% of users exceeded Medicare's annual physical therapy and SLP expenditures cap of $1860 in 2010; the percentage exceeding the cap varied substantially by treatment setting, from a low of 7% in hospitals and physician offices to a high of 34% in nursing homes. 4 In private practices, 16% of users exceeded the physical therapy and SLP cap in 2010. 4 There is limited understanding of clinical characteristics driving Part B physical therapy expenditure variation because of limitations in data available, with existing studies focusing on episode use. Ciolek and colleagues reported variation in Medicare Part B physical therapy episode expenditures by claim principal diagnosis code and diagnosis code groupings; however, most diagnosis codes were nonspecific, and most groupings were based on body site rather than diagnostic condition. 5 In Medicare beneficiaries with shoulder, lumbar, or knee musculoskeletal conditions in a single health care system, a postsurgical condition and higher baseline disability score predicted a higher number of physical therapy visits in an episode. 6 Using survey data, worse perceived health, cognitive and physical function limitations, and need for help with activities of daily living and instrumental activities of daily living were associated with more Medicare outpatient therapy visits 7 ; however, the survey data collection was not timed to coincide with therapy visits and did not include the medical diagnosis necessitating therapy, limiting the ability to draw conclusions about determinants of outpatient therapy use. 7 The association of primary diagnosis and baseline functional status with therapy use is well established in the Inpatient Rehabilitation Facility Prospective Payment System, which uses case mix groups based on etiologic diagnosis and motor functional ability. 8 In the outpatient physical therapy setting, guidelines for reporting the first-listed diagnosis code under the ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) classification system often required V-codes that largely described general services but did not provide specific information about the patient's clinical condition or disease. 9 Commonly reported V-codes, such as "V57.1, other physical therapy" 10, 3, 5 grouped together patients with potentially different diagnostic conditions and expenditures, making the claim primary diagnosis a poor predictor of expenditures. 9, 11 Other commonly reported primary diagnoses under ICD-9-CM guidelines were symptoms and signs such as "781.2, abnormality of gait," "719.41, pain in joint, shoulder region," or "719.46, pain in joint, lower leg." 10, 3, 5 Like V-codes, symptom codes potentially grouped together heterogeneous conditions that, if specified, might have better predictive value for expenditures. Guidelines for the ICD-10-CM system implemented on October 1, 2015, require the first-listed code to reflect the diagnosis, condition, problem, or other reason for the encounter/visit, when a definitive diagnosis has been established. 12 Codes describing symptoms and signs are only acceptable when a definitive diagnosis has not been established. 12 Because most outpatient physical therapy expenditure analysis to date is based on ICD-9-CM codes, the ability to make inferences about expenditure variation is limited.
In addition to limitations of ICD-9-CM data, standardized functional status data are not available on claims. Beginning January 1, 2013, the Centers for Medicare & Medicaid Services (CMS) implemented the Functional Reporting System, which requires G-codes that identify functional limitations to be reported on therapy claims. 13, 14 Forty-two G-codes and 7 severity/complexity modifiers rating percent limitation were defined for functional status reporting. An important drawback, however, is the multiplicity of tools that can be used to assign severity ratings and the resulting lack of standardization, 14 rendering the functional reporting data of limited use for classifying patients. 15 Improved diagnosis and functional status information has been described as essential for classifying patients' clinical severity to inform any redesign of Medicare's outpatient therapy payment system. 9 To better understand Medicare outpatient therapy use, CMS funded the 2008-2014 Developing Outpatient Therapy Payment Alternatives (DOTPA) project. 16 The purpose was to examine whether standardized clinical and functional status data could be used to predict therapy expenditures, and explore payment alternatives to therapy financial caps then in existence. The Continuity Assessment Record and Evaluation-Community (CARE-C) item set created for DOTPA included administrative, patient-reported, and clinician-reported data that could help assess patients' therapy needs. 16 Previous DOTPA analyses found that CARE-C primary diagnosis and baseline functional mobility, along with age, gender, and end-stage renal disease, were significant predictors of annual physical therapy expenditures. 2, 17 In addition to the individual influence of diagnosis and functional status, their interaction can be an important determinant of expenditures, as evidenced by case mix groups in the Inpatient Rehabilitation Facility Prospective Payment System. 8 The present article reports DOTPA analyses examining annual physical therapy expenditure variation by primary diagnosis and baseline functional mobility. The overall purpose was to examine spending profiles of exploratory case mix classifications based on diagnosis and mobility to assess their potential use for outpatient physical therapy expenditure differentiation and payment determination. Distinct from our risk adjustment model that included demographic and eligibility variables and provided risk estimates rather than expenditure distributions, 2, 17 case mix groups offered the advantage of being simple (based on 2 key variables), clinically intuitive, easily interpretable, and familiar to stakeholders. Our specific aims were to examine: (1) variation in Medicare annual outpatient physical therapy expenditures by patients' primary diagnosis group, and (2) variation within diagnosis groups by baseline functional mobility. We hypothesized variation in expenditures across diagnosis groups and within individual diagnosis groups by baseline mobility, with greater mobility limitation being associated with higher expenditures.
Methods
Data were collected and analyzed as described in DOTPA technical reports posted publicly.
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Sample A convenience volunteer sample of providers represented a range of setting types and geographic areas across the United States. 18 This analysis used data from community outpatient setting providers. After attending training on completion of the CARE-C item set, each provider collected data in a systematic sample of Part B patients over a 6-month period. 18 To ensure that we captured all physical therapy expenditures incurred during our analysis period (March 1, 2011, through February 29, 2012), we only included beneficiaries who were continually enrolled in the traditional Medicare Part B fee-for-service (FFS) program during this entire period, with Medicare as the primary payer.
Data Sources
Providers completed a baseline CARE-C assessment for their patient sample at episode start, including primary diagnosis and functional status. 16 We linked beneficiary-level CARE-C data with the Medicare Carrier File for Non-Institutional Claims and Outpatient File for Institutional Part B Claims. Measurement properties of CARE-C data 18, 19 and details of the file construction process 17 have been described elsewhere. We used CARE-C data to identify patients' primary diagnosis and baseline functional mobility, and claims data to calculate annual physical therapy expenditures.
Training
After providers agreed to participate, site coordinators received comprehensive web-based training on the DOTPA data collection protocol and CARE-C assessment. A help desk was available for site coordinators for assistance with functional status assessment, coding, or implementation questions. During weekly conference calls with site coordinators, the project team addressed any data collection issues and shared responses to help desk inquiries so that all sites could benefit from the answers.
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Annual Physical Therapy Expenditures
Because outpatient physical therapy expenditures were subject to an annual cap at the time of this analysis, we assessed physical therapy expenditures over a 12-month period beginning March 1, 2011, which marked the start of DOTPA data collection. This 12-month period was chosen because CARE-C data were not collected throughout the 2011 or 2012 calendar years. Annual expenditures were calculated using Medicare claims total allowed charges during the 12-month period, including both Medicare payments and beneficiary cost sharing. Because our purpose was to examine actual Medicare spending across diagnosis/mobility groups and not to conduct regional comparisons, we did not adjust expenditures for geographic variation in payment. Further, Medicare's annual physical therapy and SLP cap did not vary regionally.
Primary Diagnosis Groups
Clinicians were instructed to select a single primary diagnosis from 103 diagnoses listed on CARE-C, although some assessments reported multiple primary diagnoses. 16 To create primary diagnosis groups, we first identified individual diagnoses as etiologic or symptom/impairment. 17 Gait or balance disorder; pain syndrome; pain, not pain syndrome; complex regional syndrome; and generalized weakness were flagged as symptom/impairment diagnoses. Based on clinical reasoning, we then assigned individual primary diagnoses to mutually exclusive groups intended to reflect the underlying etiologic diagnosis necessitating therapy and to maximize within-group homogeneity in terms of clinical characteristics and therapy needs. Beneficiaries with multiple primary diagnoses were assigned to a single group based on examination of their diagnoses; for example, if a patient had "stroke" and "paralysis" listed as primary diagnoses, we assigned the patient to the "stroke" primary diagnosis group. We assigned beneficiaries with a symptom/impairment primary diagnosis to an etiologic diagnosis group if one could be identified from additional primary diagnoses, if reported, or from a secondary diagnosis reported on CARE-C. For example, if a patient had "gait or balance disorder" listed as the primary diagnosis and "Parkinson disease" as the secondary diagnosis, we assigned the patient to the "Parkinson & other progressive neurological conditions" group. When an etiologic diagnosis could not be identified, beneficiaries were assigned to an "unspecified and miscellaneous diagnoses" group. The desired minimum sample size for each group was 50.
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Functional Mobility Scores
A baseline functional mobility score was calculated based on clinician rating of patient performance on various CARE-C mobility items such as sit-to-stand and walking (Appendix). Each item was rated on a 6-point scale ranging from 6 (Independent) to 1 (Dependent); patients using assistive device(s) were scored based on their performance using the device. Each item had an "Activity Not Assessed" code, which could be used if the activity was not clinically relevant for the patient. A single walking score was assigned based on assistance needed to walk the longest distance among 4 walking distance items-ie, walk 500 ft (150 m), walk 150 ft (45 m), walk 50 ft (15 m), and walk in room once standing; similarly, a single wheelchair score was assigned based on 4 wheelchair distance items. 19 Using Winsteps, 21 we performed a Rasch analysis 22 of individual item raw scores to create a scaled functional mobility summary score for each patient ranging from 0 to 100; 0 represented the lowest functional mobility and 100 represented the highest. Rasch analysis generates scaled patient ability estimates by jointly assessing item-level responses in terms of relative task difficulty and the patient's ability to perform the task. 22 Although other item response theory models exist, Rasch models offer parsimony, interval-level properties, and sample-free calibration. Rasch scores were computed when at least 1 mobility item had been rated, and could not be computed when no item rating was present or only "activity not assessed" responses were present. In these instances, the mobility score would be missing and the associated observation excluded from mobility-related analyses. Details of the functional mobility score calculation using Rasch analyses have been reported elsewhere. 19 The CARE-C mobility items had excellent internal consistency with a Cronbach α = 0.91. 19 The CARE-C mobility items were adapted from the CARE Item Set. The original CARE mobility items showed good reliability with weighted κ values ranging between 0.558 (walk 150 ft) and 0.901 (sit-to-stand and chair/bed-to-chair transfer). 23 Unweighted κ values ranged from 0.667 (walk once standing) to 0.762 (sit-to-stand). 23 A video reliability study with "standardized" patients found substantial agreement (>76%) in responses for the lying to sitting, sit-to-stand, and chair/bed-to-chair transfer items. The walking and wheeling items showed more variable levels of agreement across disciplines, with overall agreement generally in the moderate range (50-78%).
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Data Analysis
We used Statistical Analysis Software (SAS) Studio v3.6 (SAS Institute Inc., Cary, NC, USA). To address our first aim, to examine whether annual expenditures varied across diagnosis groups, we ran analysis of variance using a .05 significance level. We ran the Tukey Honestly Significant Difference test to identify any significant pairwise comparisons. To address our second aim, to examine whether mean expenditures within each diagnosis group differed by functional mobility, we first examined the distribution of scaled mobility scores and created 4 categories based on score distributions and sample sizes (<50, 50 to <70, 70 to <97, and ≥97). We then stratified each primary diagnosis group by these categories and assessed whether the stratification provided meaningful distinction in expenditures and whether sample sizes were adequate within each stratum to support reliable inferences. Based on results of this examination, we further collapsed mobility categories and tested the mobility strata within individual diagnosis groups for statistically significant differences in expenditures, using a .05 significance level.
Role of the Funding Source
This research was funded by CMS and performed under Contract Numbers 500-2005-00029I/0012 and HHSM-500-2012-00169G. The funder specified the objectives of the project and provided overall guidance and oversight of the work. All content, interpretations, and opinions are those of the authors and not of CMS.
Results
Sample
Our sample included 66 private practices (52.0%), 30 outpatient rehabilitation facilities (23.6%), 25 hospital outpatient departments (19.7%), and 6 providers in assisted living facilities (4.7%). Our sample included 4210 beneficiaries, each with a single CARE-C assessment. The number of beneficiaries varied across providers due to differences in practice size, patient volume, and staff availability for data collection. 18 The mean [SD] number of beneficiaries per provider was 33 [29] , and range was 1 to 138. Table 1 shows provider and beneficiary distributions across census divisions. Table 2 shows the 12 primary diagnosis groups created and their component diagnoses. "Osteoarthritis, other major musculoskeletal, and unspecified musculoskeletal conditions" was the most common group, followed by "sprain, strain, bursitis, and tendonitis," "joint replacement," and "selected multiple etiologies." The "unspecified and miscellaneous diagnoses" group included diagnoses that were infrequent, not etiologic, or unlikely to be primary therapy diagnoses, such as depression. Despite its small sample, "genitourinary conditions" was kept distinct due to its unique impairments, therapy needs, and interventions. Table 3 shows the Rasch-scaled baseline functional mobility scores for the total sample and primary diagnosis groups. Functional mobility scores were missing in 45 observations (1.1%), of which 22 belonged to "unspecified and miscellaneous diagnoses," 14 to "osteoarthritis, other major musculoskeletal, and unspecified musculoskeletal conditions," and the remainder to "sprain, strain, bursitis, and tendonitis" (n = 4), "peripheral nervous system and other neurological conditions" (n = 2), "joint replacement" (n = 2), and "circulatory and pulmonary conditions" (n = 1).
Primary Diagnosis Groups
Beneficiary Demographics
Baseline Functional Mobility Scores
The mean [SD] mobility score for the total sample was 81.9 [17.0]; median, 88.7; and interquartile range, 29.1. Mobility scores were lowest for "stroke" followed by "Parkinson and other progressive neurological conditions," with only 36.6% and 42.2% of beneficiaries in these groups, respectively, having scores above 70. Mobility scores were highest for "sprain, strain, bursitis, and tendonitis," followed by "osteoarthritis, other major musculoskeletal, and unspecified musculoskeletal conditions"; 50% of beneficiaries in these groups had scores above 93.1 and 90.5, and 87.9% and 79.3% had scores above 70, respectively.
Annual Physical Therapy Expenditures
Medicare annual outpatient physical therapy expenditures for the total sample ranged from $20 to $14,690, with a mean [SD] of $1488 [$1471] (Tab. 4). Mean expenditures were highest for "stroke," followed by "Parkinson's and other progressive neurological conditions" and "joint replacement." Mean expenditures were lowest for "vertigo," followed by "genitourinary conditions." Global analysis of variance indicated a significant difference in mean expenditures across primary diagnosis groups (F = 12.73; df = 11; P < .0001). Table 5 shows that, of 66 possible pairwise expenditure differences among the 12 diagnosis groups, 25 were statistically significant based on the Tukey Honestly Significant Difference test. There were no significant differences among the 6 highest expenditure diagnosis groups flagged in Table 5 . "Joint replacement" had significantly higher costs than 6 diagnosis groups. "Stroke" and "Parkinson and other progressive neurological conditions" had significantly higher costs than 5 and 4 diagnosis groups, respectively. "Sprain, strain, bursitis, and tendonitis" and "vertigo" had significantly lower costs than 7 and 9 diagnosis groups, respectively. "Circulatory and pulmonary conditions" was significantly different only from "vertigo," having higher mean expenditures than "vertigo."
Variation in Annual Expenditures by Functional Mobility Scores
We first examined mean expenditures for primary diagnosis groups stratified by the 4 mobility categories. Most primary diagnosis groups showed a general trend of decreasing mean expenditures as mobility scores increased; however, several diagnosis-mobility categories had very small sample sizes, particularly for the extreme mobility categories. To strengthen sample sizes to allow significance testing, we collapsed mobility categories using a score cutoff of 70 to distinguish low-and high-mobility subgroups (Tab. 4). With the exception of "circulatory and a 0 = lowest mobility; 100 = highest mobility. b Functional mobility scores were missing in 45 observations, ie, 1.1% of the sample. The percent of beneficiaries in the mobility subgroups is based on the number of beneficiaries with functional mobility scores and not on the total number of beneficiaries in the sample or primary diagnosis group. Table 4 shows the number of beneficiaries in the mobility subgroups.
pulmonary conditions," all diagnosis groups showed higher mean expenditures for low-mobility compared with high-mobility subgroups. We then assessed whether a significant difference in annual expenditures was noted within each diagnosis group dichotomized by a mobility score of 70. A significant and sizable variation in expenditures by functional mobility was noted for the total sample and within 8 diagnosis groups; "vertigo" attained borderline significance (P = .072) (Tab. 4). "Parkinson and other progressive neurological conditions" showed the largest difference in mean expenditures between the low-and high-mobility subgroups, followed by "peripheral nervous system and other neurological conditions," "unspecified and miscellaneous diagnoses," "selected multiple etiologies," and "osteoarthritis, other major musculoskeletal, and unspecified musculoskeletal conditions."
Discussion
Our study demonstrates variation of annual outpatient physical therapy expenditure based on primary diagnosis and baseline functional mobility in a Medicare FFS sample. A wide range in expenditures was seen across several diagnosis-mobility groups, demonstrating the usefulness of these variables for predicting expenditures. As hypothesized, expenditures were higher for low-mobility beneficiaries within all but 1 diagnosis group, with 8 diagnosis groups demonstrating significantly different expenditures between mobility subgroups. Although additional characteristics might be important for defining case mix groups, our approach of restricting to primary diagnosis and functional mobility offers clinical validity and simplicity of interpretation and was preferable given our limited sample size. Notably, our findings are based on trends in our data; it is possible that some differences in expenditures were undetected given our small sample and a Twelve diagnosis groups stratified by 2 functional mobility categories. Because functional mobility scores were sometimes missing, the sum of beneficiaries in the mobility subgroups within the total sample or each diagnosis group in some cases does not equal the total number of beneficiaries in the sample or diagnosis group. b Significant difference in expenditures between low-and high-mobility subgroups at the .05 level using an independent sample t test. c Significant difference in expenditures between low-and high-mobility subgroups at the .05 level using a Mann-Whitney U test.
that examining expenditures in larger, more representative samples with greater functional variation could reveal additional significant patterns. Though small, our sample is similar in age and sex distribution to the national Medicare outpatient therapy population, 9 with musculoskeletal conditions also being the most common in the national population. 9 Although we have documented some expenditure differences across diagnosis-mobility groups, considerable variation within groups was also seen. Ad hoc analyses revealed that the 24 case mix groups (12 primary diagnosis groups stratified by mobility score) explained 5.5% of expenditure variation in our sample. Although low, the explanatory power of our case mix groups is identical to that of a larger regression model predicting annual expenditures in this sample based on additional demographic and eligibility variables (5.5%). 2 This suggests that additional variables added little explanatory power over primary diagnosis and functional mobility when predicting annual outpatient physical therapy expenditures. 2 One difference between the two models is that our larger regression model controlled for primary diagnosis group and functional mobility independently, without controlling for the interaction between the 2 variables.
2 Unexplained expenditure variation could in part be due to other clinical variables related to patient need, such as other functional abilities and comorbidities, which we omitted because of limited sample sizes. Unexplained variation also likely reflects patient preferences for services, provider practice patterns, and variation related to provider and regional characteristics, 9, 10, 25 factors that might not be appropriate for adjusting payments. Although socioeconomic variables might explain some variation in physical therapy use, some studies have failed to find such an association. 7, 26 Medicare's annual outpatient physical therapy and SLP cap, when in place, was the same for all beneficiaries, regardless of diagnosis, clinical characteristics, or therapy needs. When an exceptions process was in place, providers could request service provision beyond the cap by including a modifier on the claim if they deemed continued services to be medically necessary. The cap, therefore, likely did not operate as a strong constraint on spending. The Bipartisan Budget Act of 2018 repealed the annual physical therapy and SLP expenditures cap and exceptions process effective January 1, 2018, but continues to require the provider to attest to the medical necessity of services when they exceed the expenditure cap amount in prior law. 27 The same Act also changed medical review policy for therapy, first instituted in the Middle Class Tax Relief and Job Creation Act of 2012. This latter Act specified a threshold of $3700 for medical review of all Medicare Part B therapy users with expenditures above the threshold in a calendar year. 28 The Medicare Access and CHIP Reauthorization Act of 2015 allowed CMS to target this medical review such that not all claims over the threshold were subject to medical review. 29 The 2018 law lowered the medical review threshold to $3000.
The diagnosis-and function-related expenditure variation shown by our data suggests there are opportunities to employ predictable differences in outpatient physical therapy expenditures to better target administrative resources or payments directly, depending on the chosen policy. For example, given the current policy of threshold-based medical review, in an era of scarce resources, CMS could consider prioritizing cases for review when beneficiaries fall into diagnosis/functional status groups that reliable data show to be associated with lower expected expenditures. For medical review staff to be able to prioritize in this way, other new policies would be needed to facilitate reporting of diagnosis and functional status data that have the necessary reliability and predictive value. As another example, should policymakers decide to reintroduce the cap policy in the future, our findings support risk-adjusting the annual physical therapy cap for primary diagnosis and functional mobility.
To implement a risk-adjusted cap for beneficiaries who have multiple physical therapy episodes of care for varying conditions during a year, the approach would have to account for the beneficiary's most severe diagnosis or cumulative effect of multiple diagnoses and lowest functional mobility, such that the cap is based on patients' highest therapy needs. Beyond medical review or cap policies, more direct application of risk information could mean a completely different payment policy based on a system of risk-adjusted payments. Each in its own way, these 3 possible applications of expenditure predictive information have the potential to target resources to make a policy's implementation more cost-efficient.
Our study, along with others within the DOTPA project, 2 provides a proof-of-concept for the use and feasibility of assigning the primary diagnosis based on etiology of the patient's problem reported on outpatient physical therapy standardized assessments. Although the usefulness of ICD-9-CM codes for studying expenditure variation was limited, the usefulness of ICD-10-CM codes remains to be assessed. Claims diagnosis data, if useful for defining primary diagnosis groups for predicting expenditures, offer the advantage of minimal added provider burden over standardized assessments.
Any future use of functional status data for determining physical therapy payments would require collection of standardized data measuring patient function. The Medicare Payment Advisory Commission recommended collection of functional status information on outpatient therapy beneficiaries using a standardized assessment tool that reflects factors such as demographic information, diagnoses, medications, surgery, and functional limitations to classify patients. 9 Policymakers will have to ensure that any standardized functional status items implemented nationally provide adequate sensitivity and precision across the range of functional limitations observed in the physical therapy population, while being feasible and low burden. To avoid potential problems such as floor or ceiling effects in patient subgroups, policymakers could consider the pros and cons of mandating different functional status items or instruments based on patients' primary diagnosis group; to accommodate the use of different functional status instruments, this approach would work best if the payment system were redesigned to be based on distinct case mix groups or separate risk adjustment models for distinct diagnosis groups. The CARE-C mobility scale in our sample had a skewed distribution suggestive of ceiling effects, particularly in patients with musculoskeletal conditions. In more representative samples, further research could be directed at confirming these findings and, if replicated, continuing to develop the item set and scales to improve their sensitivity. Importantly, although our sample size necessitated collapsing to 2 mobility subgroups, we observed important expenditure differentiation using the initial 4 mobility categories; this suggests potential for defining case mix groups with finer mobility groupings in larger, more variable samples.
Limitations
Although our study provides important information on physical therapy expenditures not available to date, our analyses were limited by our small sample. Larger random samples with greater mobility variation would allow examination of expenditures across finer mobility subgroups, greater stability of expenditure estimates, greater generalizability, and testing of additional case mix variables that could be related to expenditures. Although our data necessitated an "unspecified and miscellaneous diagnoses" group, in practice such a group increases the potential for gameability; providers could report diagnoses resulting in assignment to this group, if associated with higher payment. Any implementation of diagnosis-based case mix groups by policymakers should ideally require specification of the primary physical therapy diagnosis to the extent possible, to minimize assignment to an "unspecified and miscellaneous diagnoses" group. The DOTPA project did not examine interrater reliability of CARE-C mobility items; however, previous studies showed good to substantial reliability of these items in postacute care settings. Further, because we categorized mobility scores into 2 groups, a small difference in scoring (eg, a few units) is not expected to have an impact on mobility categorization, except for those near the mobility cutoff score. Because we could not use a calendar year annual period, it is possible that some beneficiaries began physical therapy services prior to March 2011 and reached their annual cap earlier in our 12-month period, resulting in their expenditures being underestimated. However, the cap exceptions process likely mitigated the extent of this phenomenon. Finally, although based on 2011-2012 data, our findings remain important given the limited literature available and ongoing need for information on this topic.
Conclusions
Significant variations in physical therapy expenditures based on primary diagnosis and baseline functional mobility support the predictive value of these variables for determining expenditures. Our diagnosis-mobility groups met fundamental case mix objectives of simplicity and clinical intuition and demonstrated that meaningful cost differentiation can be achieved by adding a single dimension of functioning (ie, mobility) to the etiologic diagnosis. Our data can inform policy applications such as targeted medical review and any future efforts to reform the outpatient therapy payment system such as risk-adjusted payments or case mix group payments. Further development and validation of standardized diagnosis and functional status data in larger samples is needed to allow their use in policy applications. Refined case mix groups could also help providers prognosticate spending based on patients' diagnosis and mobility status.
